These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 10399983)

  • 1. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology.
    Morris DC
    J Am Coll Cardiol; 1999 Jul; 34(1):1-8. PubMed ID: 10399983
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
    Ferguson JJ
    Circulation; 1999 Aug; 100(6):570-5. PubMed ID: 10441090
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

  • 10. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
    Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
    Lincoff AM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
    [No Abstract]   [Full Text] [Related]  

  • 15. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
    Neumann FJ; Gawaz M; Schömig A
    Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of abciximab in interventional cardiology.
    Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
    Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
    Bhatt DL; Lincoff AM; Califf RM; Simoons ML; Tcheng JE; Brener SJ; Wolski KE; Topol EJ
    Am J Cardiol; 2000 May; 85(9):1060-4. PubMed ID: 10781752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.